EGFR and non-small cell lung carcinoma: Among patients with advanced non-small cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR) mutation is identified as the predominant target, and EGFR tyrosine kinase inhibitor (TKI) administration is the standard treatment for patients with NSCLC harboring EGFR mutation.